 |
|
Confirmed Speakers Speakers, presentation titles and timings are subject to change.
|
Trevor Wattam, GlaxoSmithKline, UK
"High Throughput Monoclonal Antibody Screening using the Biacore A100"
| |
Kenneth Miller, MedImmune, USA
"Use of SPR Biosensors in the Characterization of Therapeutic mAbs" | |
Tony Newcombe, Protherics, UK
"Evaluation of Biacore Technology for Biopharmaceutical Development"
| |
Mathilde Cabrit, Serono, France
"Biacore C versus other methods for Ab and fusion protein quantification in cell culture and purification processes" | |
Daniel Mytych, Amgen, USA
"Immunogenicity of Therapeutic Proteins" | |
Annette Zaar, Novartis, Switzerland
"Detection of Anti-Drug Antibodies (ADA) in the presence of excess Therapeutic Antibody" | |
Thomas Urbig, Micromet, Germany
"The Use of Surface Plasmon Resonance Spectroscopy from Development into Early Biomanufacturing" | |
Cornelius Fritsch, Novartis, Switzerland
"Effector Functions of Therapeutic Monoclonal Antibodies: Analysis Using Biacore Technology"
| |
Fredrik Sundberg, GE Healthcare, Sweden
"From a Global Industry Perspective: SPR Biosensor Strategies to
Improve Bio-therapeutic Discovery and Development"
| |
Gregory de Crescenzo , École Polytechnique de Montréal, Canada
"On-line Monitoring of Bioreactor Protein Production by Surface Plasmon Resonance" | |
Bruce Carrington , UCB Celltech, Slough, UK
"Antibody screening prior to cloning"
| |
Alistair Henry , UCB Celltech, Slough, UK "Antibodies, epitopes and mechanism of action'" | |
Danièle Altschuh , Centre National de Recherche Scientifique, France
"SPR characterization of gastrin binders, for the development of anti-gastrin therapies in pancreatic cancer"
| |
David Thakor , GSK, Beckenham, UK "Delivering next generation Biacore assays into the QC environment" | |
Martin Hülsmeyer, Pieris AG, Freising, Germany
"The role of SPR based assays in the discovery and lead optimization of Anticalins®, a novel class of therapeutic binding proteins" | |
|
 |
|
|
|
Choose your destination
